HEPATITIS Australia (HA) has
welcomed the PBAC positive
recommendaiton of simeprevir
(Olysio) for inclusion in the
Pharmaceutical Benefits Scheme
(PBS) for the treatment of genotype
1 chronic hepatitis C.
Hepatitis Australia ceo Helen
Tyrrell said the use of simeprevir as
an addition to pegylated interferon
and ribavirin to treat people with
genotype 1 hepatitis C was an
important step forward in the
evolution of hepatitis C treatment.
The organisation said it hoped for
an early PBS listing of simeprevir.
It was disappointed with the
PBAC’s rejection of an application
to subsidise the antiviral sofosbuvir
(Sovaldi) from Gilead, used to treat
Hepatitis C infection, Tyrrell said.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Aug 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.